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Raymond Ng1,8, W Robert McMaster1,3,9, Bruce M McManus1,2,10 and Paul A Keown1,4,7,10,13*Abstract
Background: End-stage renal failure is associated with profound changes in physiology and health, but the
molecular causation of these pleomorphic effects termed “uremia” is poorly understood. The genomic changes of
uremia were explored in a whole genome microarray case-control comparison of 95 subjects with end-stage renal
failure (n = 75) or healthy controls (n = 20).
Methods: RNA was separated from blood drawn in PAXgene tubes and gene expression analyzed using Affymetrix
Human Genome U133 Plus 2.0 arrays. Quality control and normalization was performed, and statistical significance
determined with multiple test corrections (qFDR). Biological interpretation was aided by knowledge mining using
NIH DAVID, MetaCore and PubGene
Results: Over 9,000 genes were differentially expressed in uremic subjects compared to normal controls (fold
change: -5.3 to +6.8), and more than 65% were lower in uremia. Changes appeared to be regulated through key
gene networks involving cMYC, SP1, P53, AP1, NFkB, HNF4 alpha, HIF1A, c-Jun, STAT1, STAT3 and CREB1. Gene set
enrichment analysis showed that mRNA processing and transport, protein transport, chaperone functions, the
unfolded protein response and genes involved in tumor genesis were prominently lower in uremia, while insulin-
like growth factor activity, neuroactive receptor interaction, the complement system, lipoprotein metabolism and
lipid transport were higher in uremia. Pathways involving cytoskeletal remodeling, the clathrin-coated endosomal
pathway, T-cell receptor signaling and CD28 pathways, and many immune and biological mechanisms were
significantly down-regulated, while the ubiquitin pathway and certain others were up-regulated.
Conclusions: End-stage renal failure is associated with profound changes in human gene expression which
appears to be mediated through key transcription factors. Dialysis and primary kidney disease had minor effects on
gene regulation, but uremia was the dominant influence in the changes observed. This data provides important
insight into the changes in cellular biology and function, opportunities for biomarkers of disease progression and
therapy, and potential targets for intervention in uremia.
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Chronic kidney disease (CKD) is a debilitating disorder
with profound medical and societal consequences, char-
acterized by a marked reduction in health, quality of life,
societal functioning, productivity and survival [1-4].
Pleomorphic manifestations of uremia appear as renal
function declines, and include impaired cognition and* Correspondence: keown@interchange.ubc.ca
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reproduction in any medium, provided the orexecution of higher function tasks; disordered neuro-
muscular function with muscle weakness, seizures and
sensorimotor neuropathy; altered endothelial function
with accelerated vascular disease; hematological alter-
ations with anemia, platelet dysfunction and bleeding;
endocrine and metabolic disorders typified by insulin
resistance, gonadal dysfunction, hyperparathyroidism,
bone disease and soft-tissue calcification; and disorders
of innate and adaptive immunology with features of both
inflammation and immune deficiency [1,2].Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic and clinical characteristics of study
subjects
Subjects Uremia Uremia Normal
Discovery Validation Controls
Number 63 12 20
Age (years) 47 ± 11 47 ± 13 42 ± 11
Male (%) 42 (67%) 7 (58%) 12 (60%)
Treatment status
Pre-dialysis 15 (24%) 2 (17%) N.A.
Hemodialysis 28 (44%) 7 (58%) N.A.
Peritoneal dialysis 20 (32%) 3 (25%) N.A.
Ethnicity (%)
Caucasian 47 (75%) 10 (83%) 16 (80%)
Asian 11 (17%) 2 (17%) 3 (15%)
African-american 2 (2%) 0 (0%) 0 (0%)
Other 4 (6%) 0 (0%) 1 (5%)
Primary Disease (%)
Glomerulonephritis 27 (43%) 5 (41%) N.A
Diabetes 5 (8%) 2 (17%) N.A
Polycystic Kidney Disease 11 (17%) 0 (0%) N.A
Other 20 (31%) 5 (42%) N.A
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homeostasis caused by altered synthetic functions, reduced
excretion of biological end-products, and disordered fluid
balance associated with failure of renal function. Retention
solutes found at higher levels in uremic subjects have been
identified as uremic toxins based on their association with
uremic symptoms in animals and humans with renal fail-
ure, the resolution of these symptoms when levels of these
compounds are lowered, and the toxic effects when these
substances are added to cells or tissues in vitro [5,6]. How-
ever, despite extensive investigation of the biology of
uremia, and the application of recent advances in proteo-
mics technology to investigate the causality of this syn-
drome [7], the molecular understanding of the precise
disturbances in the uremic syndrome remains incomplete.
The development of high-throughput microarray technol-
ogy, permitting simultaneous measurement of changes in
expression of multiple genes within the human genome,
provides the opportunity for novel insight into disease pro-
cesses and molecular pathways of biological dysfunction
[8,9]. Recent advances have improved the sensitivity, specifi-
city and accuracy of histological diagnosis using this tech-
nology, and the field of functional genomics is consequently
a focus of intense investigation in many disease states
[10-12]. The current study therefore examines the differen-
tial patterns of gene expression in normal subjects and pa-
tients with renal failure and outlines some of the principal
biological alterations observed in the uremic state.
Results
Subjects
Demographic and clinical details of the 95 subjects are
shown in Table 1. Subjects with stage 5 renal failure
were selected to comprise a spectrum of primary disor-
ders and treatment strategies. They were predominantly
male, Caucasian and with a mean age of 47 years; 23%
were pre-dialysis, 46% were receiving hemodialysis and
30% were on peritoneal dialysis. The principal causes of
renal disease were glomerulonephritis, polycystic kidney
disease, diabetes, and other defined disorders including
hypertension, interstitial nephritis and renovascular dis-
ease. No subjects were receiving immunosuppressive or
cytotoxic drugs. Twenty normal disease-free controls
who completed a health survey and were receiving no
prescription medication served as a comparator group.
They were predominantly male, Caucasian and had a
mean age of 42 years. Serum creatinine (658 ± 287, 95%
C.I. 569-746 umol/L vs normal: 60-115 umol/L), and
urea (25 ± 52 mmol/L, 95% C.I. 8.9-41.1 mmol/L vs nor-
mal: 2.5-6.4 mmol/L) levels were markedly increased in
uremic subjects, while peripheral white blood count
(7.45 ± 2.35, 95% CI 7.79-9.37 × 109/L vs. normal: 4.0-
11.0 × 109/L), neutrophil count (4.79 ± 1.8, 95% CI 4.97-
6.03 x109/L vs normal: 2.0-8.0 × 109/L), and lymphocytecount (1.62 ± 0.67, 95% CI 1.41-1.83 × 109/L vs normal:
1.2-3.5 × 109/L) were within normal limits.
Gene expression
Gene expression was profoundly altered in the uremic sub-
jects. Approximately 25% (n = 12,933) of transcripts in the
discovery cohort, reflecting 9,165 unique genes, were dif-
ferentially expressed with a false discovery rate (qFDR) <
0.05 compared to normal controls. Fold change (FC) values
ranged from -5.3 to +6.8, and the majority of transcripts
(65%, n = 8,442) were lower in uremia. Over one thousand
transcripts (n = 1,237) had an absolute fold change ≥ 2, of
which almost 87% (1,080) were lower in uremia. To iden-
tify the most significantly differentially expressed genes we
selected probe sets with a qFDR < 1x10-12, and a fold
change > 2. The magnitude and direction of differential ex-
pression of the 98 genes returned in the discovery cohort
are shown in the volcano diagram in Figure 1b. Segregation
of the uremic and normal subjects by hierarchical cluster
analysis is shown in the heat map in Figure 1c, and in the
principal component analysis in Figure 1d. A listing of the
functionally annotated genes which are most highly altered
is provided in Table 2.
Analysis of the validation cohort confirmed these find-
ings: 9,107 unique genes were differentially expressed
with a qFDR < 0.05; FC values ranged from -15.6 to +9.7;
and the majority of transcripts were again lower in
uremia (71% overall, > 87% with |FC| ≥ 2). All 98 highly
differentially expressed genes from the discovery cohort
were again significantly altered in the same direction
Figure 1 Differential expression of probe sets between uremic and normal subjects detected by micro-array analysis. (A) Sources of variation
estimated in a multifactorial ANOVA model. The y-axis represents signal to noise ratio of the factors. (B) Volcano diagram showing magnitude and
direction of change in gene expression. Grey points indicate the probe sets identified by ANOVA alone, and black points indicate the 110 probe sets with
a qFDR < 1x10E-12 and |FC| > 2. (C) Unsupervised cluster analysis comparing uremic and normal subjects (squared Euclidean distance, average linkage).
Each column represents an experimental subject while each row indicates a probe set. The color in each cell represents standardized log2-gene expression
values, red being low and yellow high. (D) Principal component analysis showing separation of uremic and normal subjects.
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qFDR of 3.6x10-7 (R2 = 0.960, p = 0.01) (Figure 2). The
gene list, with qFDR values for both discovery and vali-
dation cohorts, is shown in Table 2.
Both dialysis and primary kidney disease (PKD) in-
fluenced gene expression in the study cohort, although
this effect was small compared to the variation induced
by the presence or absence of uremia. When the sources
of variation in the dataset were estimated in a multifac-
torial ANOVA model, the presence or absence of uremia
had the largest influence on the variation in the dataset
(F ratio 9.55), while dialysis had a minor effect (F ratio
1.33) and the primary kidney disease, with polycystic
kidney disease (PKD) as the reference group compared
to the subgroups with renal disease secondary to dia-
betes mellitus (DM), glomerulonephritis (GN), and other
etiologies (other) has the least influence (F ratio 1.01)
(Figure 1a).Pathway analysis
The differentially expressed genes conformed to a broad
array of biological pathways and gene networks that were
under- or over-represented in uremia compared to normal
subjects. Representative examples derived from gene-set
enrichment analysis (GSEA) are shown in Figure 3. The
functions most significantly decreased (q value < 0.01) in-
volved mRNA processing, mRNA transport, and genes in-
volved in transcriptional activity; others in this category
included vesicle transport, transcription and RNA splicing,
protein export and the unfolded protein response. The
functions most significantly increased were Insulin-like
Growth Factor (IGF) activity, neuroactive ligand receptor
interaction, and the complement system; others included,
the phospholipase C mediated cascade, serotonin receptors,
and lipoprotein metabolism and lipid transport.
Highly altered genes (qFDR < 0.05; FC ≥ 1.25) showed
important perturbations in key pathways of cellular
Table 2 Most highly differentially expressed functionally defined genes in uremic subjects by comparison with
normal controls
Discovery cohort Validation cohort





ATP2A3 ATPase, Ca++ transporting, ubiquitous 1.90E-20 -2.67 1.73E-13 -3.32
MESDC1 mesoderm development candidate 1 6.41E-18 -2.01 3.66E-11 -2.03
FBRSL1 fibrosin-like 1 8.79E-18 -2.15 4.34E-14 -2.63
RNF19B ring finger protein 19B 6.82E-17 -2.48 2.35E-14 -3.52
ATPIF1 ATPase inhibitory factor 1 2.92E-16 -2.54 5.36E-09 -2.39
FKBP1A FK506 binding protein 1A, 12kDa 4.40E-16 -2.19 4.45E-11 -2.58
ILF3 interleukin enhancer binding factor 3, 90kDa 7.46E-16 -2.07 2.46E-10 -2.84
RBBP4 retinoblastoma binding protein 4 7.63E-16 -3.30 2.53E-11 -4.31
PEBP1 phosphatidylethanolamine binding protein 1 7.63E-16 -2.38 4.01E-09 -2.40
CTBP1 C-terminal binding protein 1 1.26E-15 -3.11 9.65E-11 -3.92
HINT1 histidine triad nucleotide binding protein 1 1.46E-15 -2.71 1.05E-13 -3.17
KLHL24 kelch-like 24 (Drosophila) 2.41E-15 -3.69 5.34E-12 -4.60
ILF3 interleukin enhancer binding factor 3, 90kDa 2.58E-15 -2.56 6.41E-11 -2.92
KDM1B lysine (K)-specific demethylase 1B 3.66E-15 -2.76 8.63E-09 -3.06
MTA1 metastasis associated 1 4.91E-15 -2.87 4.62E-14 -3.80
KCTD5 potassium channel tetramerisation domain containing 5 6.35E-15 -2.19 2.57E-09 -2.36
CCDC115 coiled-coil domain containing 115 1.23E-14 -2.15 5.87E-09 -2.51
SLC23A2 solute carrier family 23 (nucleobase transporters), member 2 1.42E-14 -2.02 2.02E-08 -1.94
ACAD8 acyl-CoA dehydrogenase family, member 8 1.67E-14 -2.37 1.83E-09 -2.80
RAB11FIP4 RAB11 family interacting protein 4 (class II) 1.76E-14 -2.40 3.87E-16 -4.25
RNF19B ring finger protein 19B 1.80E-14 -2.47 7.16E-12 -3.17
NONO non-POU domain containing, octamer-binding 2.60E-14 -2.09 3.78E-13 -2.64
TNRC6A trinucleotide repeat containing 6A 3.10E-14 -2.07 1.04E-14 -2.94
NDUFB8 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 8,
19kDa
3.33E-14 -2.29 8.30E-14 -2.77
OGT O-linked N-acetylglucosamine (GlcNAc) transferase (UDP-N-
acetylglucosamine:polyp
4.75E-14 -3.93 2.10E-11 -4.57
ATP5C1 ATP synthase, H + transporting, mitochondrial F1 complex,
gamma polypeptide 1
4.50E-14 -2.20 1.53E-09 -2.33
MARCH5 membrane-associated ring finger (C3HC4) 5 9.53E-14 -2.01 3.16E-07 -2.11
PPP1R8 protein phosphatase 1, regulatory (inhibitor) subunit 8 1.02E-13 -2.21 4.88E-08 -2.23
RALGAPB Ral GTPase activating protein, beta subunit (non-catalytic) 1.21E-13 -2.30 2.45E-09 -2.08
IRF2 interferon regulatory factor 2 1.49E-13 -2.20 1.94E-08 -2.47
ESYT2 extended synaptotagmin-like protein 2 1.54E-13 -2.38 4.12E-09 -2.71
BHLHE40 basic helix-loop-helix family, member e40 1.64E-13 -2.49 5.93E-09 -3.17
RABGAP1 RAB GTPase activating protein 1 1.69E-13 -2.06 3.77E-09 -2.25
GABPB2 GA binding protein transcription factor, beta subunit 2 2.09E-13 -2.15 6.64E-10 -2.31
QKI quaking homolog, KH domain RNA binding (mouse) 2.27E-13 -2.39 2.00E-08 -2.39
FLI1 Friend leukemia virus integration 1 2.37E-13 -3.81 1.29E-11 -7.39
RAB7A RAB7A, member RAS oncogene family 2.46E-13 -2.24 1.40E-09 -2.78
PDCD4 programmed cell death 4 (neoplastic transformation inhibitor) 2.52E-13 -3.69 1.01E-10 -4.69
BCL9L B-cell CLL/lymphoma 9-like 2.52E-13 -2.02 8.78E-10 -2.14
RNF166 ring finger protein 166 2.66E-13 -2.42 9.07E-10 -2.55
ACTL6A actin-like 6A 2.77E-13 -2.76 1.04E-08 -2.90
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Table 2 Most highly differentially expressed functionally defined genes in uremic subjects by comparison with
normal controls (Continued)
Discovery cohort Validation cohort




S1PR1 sphingosine-1-phosphate receptor 1 3.22E-13 -2.33 7.38E-10 -2.49
GLUD1 glutamate dehydrogenase 1 3.35E-13 -2.24 1.06E-09 -2.36
C7orf64 chromosome 7 open reading frame 64 3.35E-13 -2.68 3.61E-13 -4.25
CCDC88C coiled-coil domain containing 88C 3.36E-13 -2.27 6.82E-09 -2.17
CSAD cysteine sulfinic acid decarboxylase 3.73E-13 -2.33 1.27E-11 -2.94
ADSS adenylosuccinate synthase 4.02E-13 -2.80 2.72E-11 -4.46
SRSF1 serine/arginine-rich splicing factor 1 4.48E-13 -3.09 6.01E-10 -3.51
LOC93622 hypothetical LOC93622 4.87E-13 -2.28 1.31E-07 -2.63
ACLY ATP citrate lyase 5.37E-13 -2.01 4.00E-10 -2.69
PRF1 perforin 1 (pore forming protein) 5.40E-13 -2.18 1.79E-10 -3.28
MAPK9 mitogen-activated protein kinase 9 6.36E-13 -2.64 3.61E-07 -2.46
KLF7 Kruppel-like factor 7 (ubiquitous) 8.27E-13 -2.01 4.73E-09 -2.68
PIK3IP1 phosphoinositide-3-kinase interacting protein 1 8.63E-13 -2.08 1.98E-11 -2.38
TRIB2 tribbles homolog 2 (Drosophila) 9.60E-13 -2.35 8.64E-08 -2.67
Over-represented
MORN1 MORN repeat containing 1 5.75E-17 2.15 2.23E-14 2.92
FGF18 fibroblast growth factor 18 5.92E-17 2.55 1.73E-11 2.76
C14orf45 chromosome 14 open reading frame 45 1.59E-16 2.11 7.17E-13 2.69
ZNF205 zinc finger protein 205 7.63E-16 2.09 1.44E-14 3.99
ADARB1 adenosine deaminase, RNA-specific, B1 8.38E-16 2.20 1.24E-12 2.87
GLTSCR2 glioma tumor suppressor candidate region gene 2 8.95E-16 2.37 2.72E-12 3.12
SAP30L SAP30-like 9.54E-16 2.98 1.28E-11 3.85
ODF3B outer dense fiber of sperm tails 3B 1.07E-15 2.22 3.72E-12 2.57
SRCRB4D scavenger receptor cysteine rich domain containing, group B
(4 domains)
1.14E-15 2.16 6.71E-11 2.38
TNPO2 transportin 2 1.26E-15 2.20 1.19E-11 2.68
MAPRE3 microtubule-associated protein, RP/EB family, member 3 2.58E-15 2.35 1.82E-11 2.81
LOC100507328
LOC100508591
hypothetical LOC100507328 /// hypothetical LOC100508591 2.94E-15 2.14 1.04E-14 2.76
DUX4 double homeobox 4 /// double homeobox 4 like 2 /// double
homeobox 4 like 3 ///
3.61E-15 2.41 9.36E-15 2.98
RUNX3 runt-related transcription factor 3 3.61E-15 2.49 1.30E-12 2.44
PCGF5 Polycomb group ring finger 5 3.66E-15 2.51 5.03E-15 3.96
GPR144 G protein-coupled receptor 144 3.82E-15 2.55 1.61E-13 3.01
MAPK8IP2 mitogen-activated protein kinase 8 interacting protein 2 5.30E-15 2.29 7.39E-13 2.72
ZFPL1 zinc finger protein-like 1 1.00E-14 2.05 1.34E-13 3.04
PLEKHG5 pleckstrin homology domain containing, family G (with RhoGef
domain) member 5
1.52E-14 2.15 4.25E-11 2.45
ELAVL3 ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 (Hu
antigen C)
1.65E-14 2.32 2.97E-11 2.48
FBXO44 F-box protein 44 3.33E-14 2.09 1.70E-14 3.02
UBE2J2 ubiquitin-conjugating enzyme E2, J2 (UBC6 homolog, yeast) 3.49E-14 2.13 9.72E-11 2.43
IL34 interleukin 34 3.52E-14 2.11 1.68E-10 2.37
DKFZp761P0212 hypothetical protein DKFZp761P0212 4.11E-14 2.24 6.49E-15 2.94
SLC25A37 solute carrier family 25, member 37 4.75E-14 2.93 5.93E-10 3.17
SCNN1A sodium channel, nonvoltage-gated 1 alpha 8.43E-14 2.04 4.65E-13 2.60
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Table 2 Most highly differentially expressed functionally defined genes in uremic subjects by comparison with
normal controls (Continued)
Discovery cohort Validation cohort




SFTPC surfactant protein C 8.69E-14 2.28 5.61E-12 2.55
PDLIM7 PDZ and LIM domain 7 (enigma) 1.64E-13 2.10 5.36E-12 2.33
ARMC5 armadillo repeat containing 5 2.56E-13 2.06 1.19E-14 2.67
PLEKHN1 pleckstrin homology domain containing, family N member 1 2.58E-13 2.30 2.08E-14 3.00
GNAS GNAS complex locus 2.86E-13 2.27 1.67E-16 4.17
EPN1 epsin 1 2.87E-13 2.00 6.34E-14 2.58
BCL2 B-cell CLL/lymphoma 2 3.77E-13 2.07 1.67E-13 2.72
CHCHD5 Coiled-coil-helix-coiled-coil-helix domain containing 5 3.91E-13 2.08 8.24E-08 1.91
TFRC Transferrin receptor (p90, CD71) 4.09E-13 2.13 4.14E-13 2.46
RPS11 Ribosomal protein S11 4.14E-13 3.46 4.53E-17 7.01
C17orf51 chromosome 17 open reading frame 51 4.14E-13 2.21 4.53E-17 4.13
LMNA Lamin A/C 4.18E-13 2.23 2.78E-09 2.34
CYP11B2 cytochrome P450, family 11, subfamily B, polypeptide 2 4.98E-13 2.11 2.12E-13 3.02
TMEFF2 transmembrane protein with EGF-like and two follistatin-like
domains 2
5.64E-13 3.15 1.84E-14 5.71
GP1BB glycoprotein Ib (platelet), beta polypeptide 6.19E-13 2.49 1.52E-15 3.24
TRIM8 Tripartite motif-containing 8 8.35E-13 2.00 2.54E-10 2.36
VRTN vertebrae development homolog (pig) 8.63E-13 2.08 2.22E-11 2.18
Genes were selected by conjoint filter to identify those with smallest qFDR and highest FC.
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shown in Table 3. Functions that were lower included
the clathrin-coated vesicle endosomal pathway, the cyto-
skeletal remodeling pathway, RNA polymerase II tran-
scription, the unfolded protein response, and protein
export. The T-cell receptor signaling pathway, MHC-
class II and the T-cell receptor alpha / beta heterodimer,
the co-associated CD3 and CD4 molecules and a variety
of downstream signaling components of the T-cell
receptor pathway were importantly lower, as were those
central to the immune synapse, the CD28 receptor path-
way, the IL-2 response and signaling pathway. STAT3,
SMAD3, MAPK1, c-Fos, Caspase -8 and -9, MICB, and
WNT1 were markedly inhibited, influencing critical
intracellular events of signal transduction, activation and
regulation of cell proliferation. In contrast, MAP2K3,
JAK1, amyloid beta 42, ubiquitin, and TNF beta were
higher, influencing events involved in intracellular
signaling, the inflammatory-related respiratory burst and
the response to stress and injury. Expression of the
erythropoietin receptor gene was elevated, although
down-stream signaling steps through STAT1, 3 and 5
and others were repressed, while ligand receptor inter-
action encompassing events in hormone binding, ion
channel activation, HDL-mediated lipid transport,
histidine metabolism and phenylalanine metabolism
were also higher.Network analysis
Differentially expressed genes in uremic subjects encoded a
broad range of macromolecular functions and metabolic
networks across all locations within the cell. Many of these
diverse functions were regulated through key gene networks.
Two representative networks demonstrating the central
roles of cMYC (down-regulated) and SP1 (up-regulated) are
shown in Figure 4. Other transcription factors playing cen-
tral roles in regulating nuclear and cellular biosynthetic and
metabolic processes included P53, AP1, NFkB, HNF4 alpha,
HIF1A, c-Jun, STAT1, STAT3 and CREB1.
Discussion
Chronic kidney disease is a global problem, with an esti-
mated prevalence of more than 20% in those over 64 years
of age [13] and health care cost approaching $2 billion per
year in Canada and 7% of Medicare expenditures in the U.
S. [14,15]. Dialysis may ameliorate the symptoms of uremia,
but inadequate clearance of uremic toxins ultimately results
in progressive illness manifest by chronic injury to the vas-
cular tree, skeleton, neuronal networks and other critical
bodily systems [1,2]. The European Uremic Toxin Work
Group has listed more than 100 retained solutes that vari-
ably impair cellular function or survival and are important
contributors in the expression of uremia [16]. Among these,
small molecules that bind reversibly to serum proteins and
“middle molecule” range proteins of 10-30KD are difficult
A B
C D
Figure 2 Visualization of data in the Validation Cohort, showing differential expression, Volcano Plot, Principal Component Analysis
and Hierarchical clustering of 100 most highly differentially expressed transcripts from the Discovery Cohort. A: Fold change
comparison. Fold changes were sorted by value in the discovery cohort (red line). The x-axis represents the numbered probe sets. Fold change
direction is identical and in similar range for all probe sets in both cohorts. B: Volcano plot showing the qFDR and the fold changes for the 110
probe sets in the validation cohort after ANOVA. The qFDR and fold change are comparable in both cohorts. C: PCA utilizing the 110 probe sets
from the validation cohort. The two groups are clearly separated indicating that the expression patterns of the transcripts are comparable in both
cohorts. D: Hierarchical clustering of Normal and Uremic samples from the validation cohort based on 110 probe sets from the discovery cohort
showing clear separation of both subject sets.
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may become irreversibly altered through posttranslational
modifications in the uremic environment, resulting in
changes in structure and function [5].
The data reported here show that uremia is accompanied
by profound changes in gene expression reflecting perturb-
ation in many aspects of cell biology [17]. Genes encodingregulators of transcription, mRNA transport, protein syn-
thesis, export and localization, and cell-cycle progression
are lower, and transcripts associated with membrane lipid
metabolism involving phosphotidylinositol 3,4,5; n-acyl
sphingosine; ceramide and others are significantly lower in
uremia. Cytoskeletal remodeling is markedly impaired, and
expression of genes for the binding proteins talin and actin,
Figure 3 Gene Set Enrichment Analysis (GSEA) by gene set permutation. Blue dots represent enriched probe sets of the gene set, blue
circles represent probe sets of the gene set that are not enriched, and grey dots represent all other probe sets on the array. X and Y axes are
mean signal intensities in log2 scale. Source: http://www.broadinstitute.org/gsea/msigdb/index.jsp, MSigDB database v3.0 updated Sep 9, 2010.
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ments, regulators such as tuberin, and RAS-superfamily
GTP-ases integral to cytoskeletal re-organization are sub-
stantially reduced. Interestingly, transcripts central to
apoptosis pathways including the Fas receptor, FADD,
Granzyme B and members of the caspases family are also
reduced arguing against a principal role in premature cell
death [18,19].
Among the complex endocrine changes associated
with uremia [20], we observe that parathyroid hormone
gene (PTH) expression is enhanced, consistent with the
elevated hormone levels observed [1]. The Wnt signaling
pathway is activated in hyperarathyoidism [21] and is
strongly represented in the current dataset by probe sets
including Casein kinase 1, Rac1, c-Fos, and p130. Smad2
and Smad4, TGFBR2 and other members of the TGF-
beta and BMP pathways, among the most highly
dysregulated probe sets in uremia, may reflect altered
bone metabolism [22]. Expression of genes coding for
the pituitary hormones was unchanged, while the prolac-
tin releasing hormone (PRLH) gene was increased and
prolactin regulatory element binding (PREB) gene re-
duced. Erythropoietin production is normally decreased
in uremia. Possibly as a compensation to this, the
erythropoietin receptor gene expression was significantlyhigher, while the down-stream signaling steps were re-
pressed, perhaps contributing to the anemia of renal fail-
ure [1]. The effect of uremia on platelet function may be
reflected by changes in the probe sets coding for
PKCeta, Rac1, ATP2A3, and GP-IB (platelet glycoprotein
I beta) and other members of the “platelet aggregation”
network.
Insulin resistance is an important endocrine effect of
uremia, and is believed to contribute to accelerated vascular
disease and muscle wasting [23]. Although insulin binds
normally to its receptor in uremia, and receptor density is
unchanged, the transfer of insulin resistance by uremic
serum suggests a direct contribution of uremic toxins. The
data reported here indicates that insulin receptor gene
(INSR) expression is modestly increased but the transcrip-
tional level of insulin receptor substrate 2 (IRS2) is lower
than normal. This cytoplasmic signaling molecule mediates
the effects of insulin, acting as a molecular adaptor between
diverse receptor tyrosine kinases and downstream effectors,
and mice lacking IRS2 have a diabetic phenotype. Failure of
post-receptor signaling has been noted as a fundamental
mechanism of insulin resistance in uremic animals and in
other disorders including injury, infection, aging and obes-
ity and may reflect an important biological mechanisms in
uremia [24].
Figure 4 Pathway analysis showing principal pathways altered
in relation to the transcription factors c-Myc and SP1. Blue wavy
icons: generic binding proteins, yellow arrows: generic enzymes,
green arrows: regulators. Blue dots: under-represented, Red dots:
over-represented. The complete legend can be found at: http://ntp.
niehs.nih.gov/ntp/ohat/diabetesobesity/Wkshp/MC_legend.pdf.
Table 3 Principal gene pathways altered in uremia
Principal gene pathways altered in uremia p-value Ratio*
Transport: Clathrin-coated vesicle cycle 8.039E-23 60 / 71
Cytoskeleton remodeling: TGF, WNT and
cytoskeletal remodeling
2.990E-19 77 / 111
Cytoskeleton remodeling: Cytoskeleton
remodeling
3.226E-17 70 / 102
Development: EPO-induced Jak-STAT pathway 2.658E-16 33 / 35
Translation: Regulation of EIF4F activity 2.083E-15 43 / 53
Chemotaxis: CXCR4 signaling pathway 2.445E-14 31 / 34
Development: GM-CSF signaling 4.953E-14 40 / 50
Immune response: T cell receptor signaling
pathway
5.938E-14 41 / 52
Immune response: IL-2 activation and signaling
pathway
1.410E-13 39 / 49
Oxidative phosphorylation 1.787E-13 66 / 105
Immune response : Immunological synapse
formation
2.407E-13 44 / 59
Development: Flt3 signaling 2.595E-13 36 / 44
Signal transduction: Activation of PKC via G-
Protein coupled receptor
5.244E-13 40 / 52
Cell cycle: Influence of Ras and Rho proteins on
G1/S Transition
1.552E-12 40 / 53
Immune response: Role of DAP12 receptors in NK
cells
4.346E-12 40 / 54
Immune response: BCR pathway 4.346E-12 40 / 54
Transcription: NF-kB signaling pathway 4.945E-12 32 / 39
Development: PIP3 signaling in cardiac myocytes 9.777E-12 36 / 47
Development: EGFR signaling pathway 1.026E-11 44 / 63
*# genes in list in pathway/# genes in pathway.
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of patient survival in uremia. Although the precise cause
remains unclear, insulin resistance, inflammation, and ele-
vated circulating levels of ghrelin and leptin have been im-
plicated in this process [25-27]. While transcription of
Ghrelin or Leptin genes was not altered, expression of
both the leptin receptor overlapping transcript (LEPROT)
and transcript-like 1 (LEPROTL1) was increased, which
may influence leptin and GH receptor expression and their
receptor-mediated signaling [28]. Growth factor and insulin-
like growth factor (IGF) gene expression were unchanged,
while IGF receptor-1 expression was suppressed and post-
receptor signaling through the 14-3-3 protein complex was
lower, which may influence protein synthesis, muscle and
bone metabolism [29]. AKTIP was lower in uremia, consis-
tent with the proposals that insulin resistance may promote
muscle wasting by inhibition of PI3K/Akt leading to activa-
tion of caspase 3 and the ubiquitin-proteasome proteolytic
[27]. Activation of the ubiquitin-proteosome system (UPS),
caused by inflammation, acidosis and other factors is a fea-
ture of muscle wasting conditions including sepsis and
uremia [30]. However, probe sets of the protein-degradation
machinery, e.g. UBE2E1, USP32, UBE2Q2, and UBR3 wereinhibited in uremia, indicating that evaluation of the
ubiquitin-proteosome machinery requires more detailed
investigation.
Uremia is characterized by a complex alteration in the
immune response [31]. Systemic inflammation, manifest by
elevations in inflammatory markers including C-reactive
protein, interleukin-6, and tumor necrosis factor α [31], is
accompanied by polymorph and monocyte dysfunction
[32], and impaired cellular immunity with altered T cell
function and proliferation [33]. The data here reflect many
of these events at the genomic level. Gene expression
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metabolism is higher in uremia, while transcripts associated
with the clathrin-coated vesicle endosomal pathway are
markedly reduced consistent with a defect in phagocytosis.
Key genes in the immune synapse and the T-cell receptor
signaling pathway were reduced, including MHC-class II
and the T-cell receptor alpha / beta heterodimer, the
co-associated CD3 and CD4 molecules and a variety of
downstream signaling components of the T-cell receptor
pathway, the CD28 receptor pathway and the IL-2 re-
sponse and signaling pathway.
Peripheral blood is a common matrix for investigation
of human biology and biomarkers, but is subject to certain
limitations which may influence the results observed.
Fluctuation in peripheral formed elements may influence
gene expression patterns, and while we have attempted to
minimize this by selecting candidates whose peripheral
blood counts resemble as closely as possible those of the
normal control population this does not eliminate all bias.
In addition, the presence of globin mRNA which repre-
sents up to 70% of the total expressed transcripts in per-
ipheral blood, reduces the sensitivity of microarray
analysis, particularly in detecting differences among genes
transcribed at low levels [34-36]. Strategies to reduce glo-
bin mRNA were not employed in these studies, since pre-
liminary data indicated the profound magnitude of the
changes in uremia, but it is possible that this step may en-
hance the sensitivity of these results and define further
critical biological alterations in the uremic state [34].
Conclusions
In summary, the data presented show that uremia is accom-
panied by a marked change in expression of genes involved
in a broad range of physiological processes [1,6]. Many of
these genes appear to be coordinately regulated through
networks whose activity is suppressed or enhanced by
individual transcription factors. Recent work suggests that
epigenetic regulation may exert an important influence in
these changes, and that histone hypermethylation may
contribute to both the reduced expression and increased
inflammatory mechanisms observed in this setting [37,38].
These observations provide an important insight into the
biology of the uremic syndrome and a foundation for more
detailed proteogenomic exploration of uremic toxicity.
They provide a foundation for exploration of biomarkers
for measurement of treatment efficacy, and offer a starting
point for identification of new therapeutic targets regulat-
ing gene effects to mitigate the consequences of this syn-
drome and restore biological homeostasis.
Methods
Study design
The study was conducted at the University of British
Columbia and approved by the human ethics researchboard. A case-control design was employed to compare
gene expression in patients with chronic renal failure and
healthy controls. Patients with stage 5 renal disease aged
18 to 75 years, who were clinically stable awaiting renal
transplantation, were not receiving immunosuppressive
medications, and provided written informed consent were
enrolled into the study. Patients were treated according to
Canadian Guidelines for Chronic Kidney Disease [39].
Dialysis was instituted at a calculated GFR of less than 15
ml/min/m2; peritoneal dialysis was normally performed
by continuous ambulatory peritoneal dialysis (CAPD) or a
cycler, and hemodialysis (HD) was normally performed 3
times per week for an average of 12 hours. Normal con-
trols of comparable age and gender who were screened to
ensure freedom from known illness and medical therapy
served as comparators.
Study samples
Early morning, fasting, whole blood samples (5 ml) were
drawn into PAXgeneTM tubes (Qiagen Inc) before dialysis
or anticoagulation, and stored at -80° until analysis. Total
RNA was extracted from the cells using a PAXgeneTM
Blood RNA Kit, and the integrity and concentration deter-
mined using the Agilent 2100 BioAnalyzer (Agilent Tech-
nologies, Palo Alto, CA). Gene expression was analyzed at
the CAP/CLIA certified Genome Core at the Children’s
Hospital, Los Angeles, CA using Affymetrix Human Gen-
ome U133 Plus 2.0 arrays (Affymetrix Inc). Strategies to
reduce globin mRNA were not employed in this study,
since preliminary data demonstrated a marked difference
between expression patterns in uremic and normal sub-
jects. Quality of the samples, hybridization, chips and
scanning was reviewed using the BioConductor packages
Affy version 1.16.0 and affyPLM version 1.14.0. Data
import, normalization and statistical analysis were per-
formed using the Partek Genomics Suite, version 6.5
(Partek, St Louis, MI). RMA background correction and
quantile normalization were applied followed by log2-
transformation. An unsupervised raw expression filter was
applied with a threshold of signal intensity of 6 in a num-
ber of samples equal to 75% of the smallest sample group.
RNA samples for qPCR were reverse transcribed using
SuperScript III First-Strand Synthesis kit (Invitrogen).
qPCR assays were performed using gene-specific primers
and Taqman gene expression assays (Applie Bioscience)
on the ABI 7900 HT. Expression levels were normalized
against β-actin.
Statistical analysis
Statistical significance was determined by ANOVA,
followed by multiple test corrections (qFDR). Probe sets
were ranked by fold change after application of a qFDR
threshold. A qFDR value < 0.05 was considered significant.
Gene-set enrichment analysis (GSEA) was performed using
Scherer et al. BMC Medical Genomics 2013, 6:23 Page 11 of 12
http://www.biomedcentral.com/1755-8794/6/23GSEA software (www.broad.mit.edu/gsea). The dataset was
not collapsed to gene symbols, probe sets were ranked by
signal to noise metric, and the number of gene-set per-
mutations was 1000. Biological interpretation was aided
by knowledge mining using NIH DAVID (http://david.
abcc.ncifcrf.gov/), MetaCore (www.GeneGo.com) and
PubGene (www.Pubgene.org). Gene Ontologies and Net-
works in GeneGo MetaCore were prioritized based on
their statistical significance with respect to the size of the
intersection of the dataset and the set of genes/proteins
corresponding to the Gene Ontology category or network
(www.portal.genego.com/help/p-value_calculations.pdf).
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